Drugs that contain Liraglutide Recombinant
1. List of Saxenda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(7 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 2 months ago) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 2 months ago) | |
| US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(8 months ago) | |
|
US6899699
(Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(8 months ago) | |
|
US9486588
(Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(8 months ago) | |
|
US8672898
(Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(8 months ago) | |
|
US8846618
(Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(2 months ago) | |
|
US6268343
(Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(a month ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(3 months from now) | |
|
US8579869
(Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(9 months from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 1 month from now) | |
|
US7762994
(Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 7 months from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
|
US8114833
(Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(2 years from now) | |
|
US8684969
(Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(3 years from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
|
US9616180
(Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(3 years from now) | |
|
US9861757
(Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(3 years from now) | |
|
US9108002
(Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(3 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(3 years from now) | |
|
US8920383
(Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(3 years from now) | |
|
US9775953
(Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(3 years from now) | |
|
US10220155
(Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(3 years from now) | |
|
USRE46363
(Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(3 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(3 years from now) | |
|
US9687611
(Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(4 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(4 years from now) | |
|
US9457154
(Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(5 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(8 years from now) | |
|
US9132239
(Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(9 years from now) | |
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
|
US9968659
(Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 4, 2023 |
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
57
United States
28
Denmark
28
European Union
15
Japan
13
Spain
13
China
10
Poland
9
Australia
8
Russia
8
Canada
7
Austria
7
Germany
6
Brazil
6
Portugal
3
Slovenia
3
Hungary
3
Korea, Republic of
2
South Africa
2
Mexico
1
Israel
1
Turkey
1
Hong Kong
1
Morocco
1
Philippines
1
Croatia
1
Cyprus
1
Chile
1
RS
2. List of Victoza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6268343 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2022
(7 months ago) | |
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846618 | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Jun, 2022
(8 months ago) | |
|
US8846618
(Pediatric) | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Dec, 2022
(2 months ago) | |
|
US6268343
(Pediatric) | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Feb, 2023
(a month ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(3 months from now) | |
|
US8579869
(Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(9 months from now) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 1 month from now) | |
|
US7762994
(Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 7 months from now) | |
|
US8114833
(Pediatric) | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(2 years from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(9 years from now) | |
|
US9265893
(Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(9 years from now) | |
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
|
US9968659
(Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 17, 2022 |
| Pediatric Exclusivity (PED) | Dec 17, 2022 |
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents
22
United States
18
Denmark
14
European Union
7
Spain
7
China
7
Japan
5
Australia
5
Portugal
5
Poland
4
Austria
4
Russia
4
Germany
4
Canada
3
Slovenia
3
Hungary
3
Brazil
2
Mexico
2
Korea, Republic of
1
Israel
1
South Africa
1
Turkey
1
Hong Kong
1
Morocco
1
Philippines
1
Croatia
1
Cyprus
1
Chile
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic